Approval of Esketamine for Treatment-Resistant Depression

The Lancet Psychiatry - United Kingdom
doi 10.1016/s2215-0366(19)30533-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Approval of Esketamine for Treatment-Resistant Depression – Authors' Reply

The Lancet Psychiatry
PsychiatryBiological PsychiatryMental Health
2020English

Approval of Esketamine for Treatment-Resistant Depression – Author's Reply

The Lancet Psychiatry
PsychiatryBiological PsychiatryMental Health
2020English

156 Improvement in Disease Severity in Patients With Treatment-Resistant Depression Following Treatment With Intranasal Esketamine

CNS Spectrums
PsychiatryMental HealthNeurology
2018English

Ketamine for Treatment-Resistant Unipolar Depression

CNS Drugs
PsychiatryMental HealthNeurologyPharmacology
2012English

Treatment Resistant Depression in Women With Peripartum Depression

BMC Pregnancy and Childbirth
GynecologyObstetrics
2019English

Treatment-Resistant and Multi-Therapy-Resistant Criteria for Bipolar Depression: Consensus Definition

British Journal of Psychiatry
MedicinePsychiatryMental Health
2018English

Treatment-Resistant Depression in Later Life

Journal of Psychiatry and Neuroscience
MedicinePsychiatryBiological PsychiatryMental HealthPharmacology
2015English

Systematic Review of Management for Treatment-Resistant Depression in Adolescents

BMC Psychiatry
PsychiatryMental Health
2014English

Current Nosology of Treatment Resistant Depression: A Controversy Resistant to Revision

Clinical Practice and Epidemiology in Mental Health
PsychiatryEpidemiologyMental Health
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy